← BrightSpring Health Services, Inc. Common Stock overview

BrightSpring Health Services, Inc. Common Stock vs NeoGenomics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

August 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Latest
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

NeoGenomics Inc (NEO)

Q3 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

August 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

Latest
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.